BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

18 reasons why BPAX should be trading between $3 to $4 even without Bio-t-gel or Libigel

I have made this easy for anyone who wants to compare product pipelines I have also included the company's Market Cap. If Bio-t-Gel is approved and the information below sinks in you are looking at a $4 to $5 share price on February 14th.

Biosante Product Pipeline $98.47 million
Overview
Cancer Vaccine

Other companies with Annual revenue less then $10. million and a negative Net Annual Income

Novavax $162.11 million

Cell Therapeutics $212. million

Keryx $234.38 million

Amicus Therapeutics $234.96 million

Corcept $259.43 million

Cadence pharma $268.46 million

YM bioscience $278.94 million

Chelsea Therapeutics $308.00 million

MannKind $316.53 million

Anthera $323.17 million

Progenics $337.29 million

Oncothyreon $341.89 million

Aegerion $356.93 million

Ziopharm $364.16 milliom

Oncolytics Biotech $366.89 million

Raptor Pharma $370.72 million

Avanir $401.38 million

Map Pharma $472.40 million